ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Once-Daily Prolonged-Release Tacrolimus versus Twice-Daily Tacrolimus in Liver Transplantation: A Meta-Analysis

R. Deng, B. Huang, Y. Shi, Y. Ma.

Organ Transplantation Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.

Meeting: 2018 American Transplant Congress

Abstract number: C216

Keywords: Immunosuppression, Rejection

Session Information

Date: Monday, June 4, 2018

Session Name: Poster Session C: Liver: Immunosuppression and Rejection

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall 4EF

Related Abstracts
  • Is Once-Daily Extended-Release Tacrolimus Better Than Twice-Daily Standard-Release Tacrolimus? A Meta-Analysis of Randomized Controlled Trials.
  • A Change in Insulin Sensitivity and Lipid Profile in Renal Transplant Recipients Converted from Cyclosporine or Standard Release Tacrolimus to Once-Daily Prolonged Release Tacrolimus.

Background: A prolonged-release formulation of tacrolimus has been developed to provide once-daily dosing, with similar efficacy and safety to the standard twice-daily dosing and it may offer distinct advantages over an immediate-release action .We aimed to identify, appraise, and synthesize the current evidence comparing the efficacy and relative safety of the recently introduced daily versus standard twice-daily tacrolimus administration in liver transplantation.

Methods: We systematically searched for all randomized controlled trials and non-randomized controlled trials studies that compared the outcomes of daily versus twice-daily tacrolimus formulation in liver transplant recipients. Pubmed,web of science,cochane.Four trials were founded.Risk ratios and 95% confidence intervals (CI) were calculated to compare the combined data between groups that were treated with tacrolimus QD versus tacrolimus BID.

Results: Three randomized controlled trials (n=4967) and one non- randomized controlled trials (n=30) were included in our review. No significant differences were found between the two regimen in incidence of Biopsy-Proven Acute Rejection,renal failure, diabetes mellitus, one year graft survival, or one year patient survival. However,patients treated with a prolonged-release formulation of tacrolimus were more likely to get infected with a risk ratio of 1.27 (95% CI = 1.03–1.55)compared to the standard twice-daily dosing, and statistically significantly(P=0.02)

Conclusions: Once-daily tacrolimus dosing appears to be as effective as twice-daily tacrolimus dosing but has a more possibility of infection occurrence after liver transplantation.

CITATION INFORMATION: Deng R., Huang B., Shi Y., Ma Y. Once-Daily Prolonged-Release Tacrolimus versus Twice-Daily Tacrolimus in Liver Transplantation: A Meta-Analysis Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Deng R, Huang B, Shi Y, Ma Y. Once-Daily Prolonged-Release Tacrolimus versus Twice-Daily Tacrolimus in Liver Transplantation: A Meta-Analysis [abstract]. https://atcmeetingabstracts.com/abstract/once-daily-prolonged-release-tacrolimus-versus-twice-daily-tacrolimus-in-liver-transplantation-a-meta-analysis/. Accessed December 6, 2019.

« Back to 2018 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Penis Transplantation: First U.S. Experience.
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Tacrolimus Dose and Trough Blood Levels in a US Liver Transplant Population
  • Penis Transplantation: First U.S. Experience.
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Tacrolimus Dose and Trough Blood Levels in a US Liver Transplant Population
  • Tacrolimus Dose and Trough Blood Levels in a US Liver Transplant Population

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2019 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

wiley-new-logo

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.